MedTrace Logo

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

NCT04316936 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-06-15

No results posted yet for this study

Summary

This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain following cataract surgery.

Conditions

  • Cataract Surgery

Interventions

DRUG

Omidria

phenylephrine 1% and ketorolac 0.3% intraocular solution

DRUG

Dextenza (dexamethasone ophthalmic insert) 0.4mg

intracanalicular dexamethasone insert

DRUG

Dexycu, 9% Intraocular Suspension

dexamethasone intraocular suspension

DRUG

Prednisolone Acetate 1%

standard postoperative ophthalmic drop regimen

Sponsors & Collaborators

  • Ocular Therapeutix, Inc.

    collaborator INDUSTRY

  • Silverstein Eye Centers

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-10
Primary Completion
2020-12-23
Completion
2020-12-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04316936 on ClinicalTrials.gov